HomepageATYR • NASDAQ
add
aTyr Pharma Inc
$ 6,03
Na sluitingstijd:(3,65%)+0,22
$ 6,25
Gesloten: 12 sep, 19:59:57 GMT-4 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$ 5,26
Dag-range
$ 5,22 - $ 6,50
Jaar-range
$ 1,67 - $ 7,29
Beurswaarde
590,86 mln. USD
Gem. volume
4,19 mln.
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | — | — |
Bedrijfskosten | 4,93 mln. | 47,49% |
Netto inkomsten | -19,53 mln. | -19,78% |
Netto winstmarge | — | — |
Winst per aandeel | -0,22 | 4,35% |
EBITDA | -20,15 mln. | -17,56% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
| (USD) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 80,35 mln. | 2,38% |
Totale activa | 101,53 mln. | -4,16% |
Totale passiva | 26,88 mln. | 9,64% |
Totaal aandelenvermogen | 74,66 mln. | — |
Uitstaande aandelen | 97,99 mln. | — |
Koers-boekwaardeverhouding | 6,49 | — |
Rendement op activa | -51,09% | — |
Rendement op kapitaal | -57,98% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -19,53 mln. | -19,78% |
Operationele kasstroom | -13,89 mln. | 32,06% |
Kasstroom uit beleggingen | 3,30 mln. | -50,94% |
Kasstroom uit financiering | 17,90 mln. | 33,56% |
Nettomutatie in liquide middelen | 7,30 mln. | 2.375,39% |
Vrije kasstroom | -6,43 mln. | 51,63% |
Over
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
Opgericht
1 jan 2005
Website
Werknemers
61
